2-(1H-pyrrolo[3,2-c]pyridin-3-yl)acetonitrile | 39676-14-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 2-(1H-pyrrolo[3,2-c]pyridin-3-yl)acetonitrile
• CAS: 39676-14-7
• 化学式: C₉H₇N₃
• 分子量: 157.175
• InChiKey: TYABGZSXMGEYLU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  52.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-(1H-pyrrolo[3,2-c]pyridin-3-yl)acetonitrile 在 ammonium hydroxide 、 Rh/Al₂O₃ 、 氢气 作用下， 以 乙醇 、 水 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 生成 1H-吡咯并[3,2-c]吡啶-3-乙胺
  参考文献：
  名称：

  Optimization of the in Vitro Cardiac Safety of Hydroxamate-Based Histone Deacetylase Inhibitors

  摘要：

  Histone deacetylase (HDAC) inhibitors have shown promise in treating various forms of cancer. However, many HDAC inhibitors from diverse structural classes have been associated with QT prolongation in humans. Inhibition of the human ether a-go-go related gene (hERG) channel has been associated with QT prolongation and fatal arrhythmias. To determine if the observed cardiac effects of HDAC inhibitors in humans is due to hERG blockade, a highly potent HDAC inhibitor devoid of hERG activity was required. Starting with dacinostat (LAQ824), a highly potent. HDAC inhibitor, we explored the SAR to determine the pharmacophores required for HDAC and hERG inhibition. We disclose here the results of these efforts where a high degree, of pharmacophore homology between these two targets was discovered. This, similarity prevented traditional strategies for mitigating hERG binding/modulation from being successful and novel approaches for reducing hERG inhibition were required. Using a hERG homology model, two compounds, 11r and 25i, were discovered to be highly efficacious with weak affinity for the hERG and other ion channels.

  DOI：

  10.1021/jm200388e
• 作为产物：
  描述：

  N,N-dimethyl-1-(1H-pyrrolo[3,2-c]pyridin-3-yl)methanamine 以 四氢呋喃 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.0h， 生成 2-(1H-pyrrolo[3,2-c]pyridin-3-yl)acetonitrile
  参考文献：
  名称：

  [EN] FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERARY
  [FR] DIAMIDES IMIDODICARBONIMIDIQUES LIÉS À UN ALKYLÈNE BICYCLIQUE FUSIONNÉ, PROCÉDÉS DE SYNTHÈSE ET UTILISATIONS DANS UNE THÉRAPIE

  摘要：

  本发明提供了新型的融合的双环烷基亚乙基连接的咪唑二氨基碳亚胺二酰胺。具体来说，本文描述了N-[2-(吲哚-3-基)烷基]-连接的咪唑二氨基碳亚胺二酰胺和N-[2-(吡咯吡啶-3-基)烷基]-连接的咪唑二氨基碳亚胺二酰胺（化合物的结构式（I）或结构式（II）），以及其用途。本发明的化合物被认为是有机阳离子转运体选择性化合物，可用于治疗由于5'腺苷单磷酸活化蛋白激酶（AMPK）活性降低而引起的疾病和症状。

  公开号：

  WO2018106907A1

文献信息

• [EN] FXR MODULATORS AND METHODS OF THEIR USE<br/>[FR] MODULATEURS DE FXR ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ALIOS BIOPHARMA INC

  公开号：WO2017143134A1

  公开（公告）日：2017-08-24

  The present disclosure is directed to modulators of farnesoid X receptor. Methods of making and using these modulators is also described.

  本公开涉及法尼索酸X受体的调节剂。同时还描述了制备和使用这些调节剂的方法。
• Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
  申请人：Wyeth

  公开号：US20030171395A1

  公开（公告）日：2003-09-11

  The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor. 1

  本发明提供了一种I式化合物及其用于治疗与5-HT6受体相关或受其影响的疾病的用途。
• AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
  申请人：BERNOTAS Ronald Charles

  公开号：US20080114023A1

  公开（公告）日：2008-05-15

  The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.

  本发明提供一种公式I的化合物以及其在治疗与或受5-HT6受体影响的疾病方面的应用。
• Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy
  申请人：NovaTarg, Inc.

  公开号：US11261157B2

  公开（公告）日：2022-03-01

  The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3-yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3-yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5′ adenosine monophosphate-activated protein kinase (AMPK).

  本发明提供了新颖的融合双环烯基连接的咪唑二碳酰亚胺二酰胺。特别是，本发明描述了 N-[2-(吲哚-3-基)亚烷基]连接的咪唑二碳酰亚胺二酰胺和 N-[2-(吡咯并吡啶-3-基)亚烷基]连接的咪唑二碳酰亚胺二酰胺（式 (I) 或式 (II) 的化合物）及其用途。本发明的化合物被认为是有机阳离子转运体选择性化合物，可用于治疗由 5′单磷酸腺苷激活蛋白激酶（AMPK）活性降低引起的疾病和病症。
• FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY
  申请人：NovaTarg, Inc.

  公开号：US20190345103A1

  公开（公告）日：2019-11-14

  The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3-yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3-yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5′ adenosine monophosphate-activated protein kinase (AMPK).